Evidence map›Paper›PMID 36171565›Full record

ArticleCancer biology & therapy2022

High tumor amplification burden is associated with

Rushikesh S Joshi, Amelie Boichard, Jacob J Adashek, Razelle Kurzrock

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Rushikesh S JoshiSchool of Medicine, University of California San Diego, La Jolla, CA, USA.
Amelie BoichardDepartment of Molecular Cancer Genetics, University of Strasbourg Hospitals, Strasbourg, France.
Jacob J AdashekDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Hospital, Baltimore, MD, USA.ORCID 0000-0003-4272-312X
Razelle KurzrockMCW Cancer Center and Genomic Sciences and Precision Medicine Center, Medical College of Wisconsin, WIS, USA.ORCID 0000-0003-4110-1214
Johns Hopkins Hospital · USMedical College of Wisconsin · USUniversité de Strasbourg · FRUniversity of California San Diego · US

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jesse Nodora · 1985 to 2026
$124.9M
NCI NIH HHS P30 CA023100
6 · The paper itself

Abstract

Next-generation sequencing data is fundamentally changing the clinical management of patients with cancer. The most frequent genomic alterations in malignancy are mutations and amplifications, with a subset of tumors having multiple amplifications - "amplificators". We sought to understand the molecular correlates of high tumor amplification burden in a pan-cancer context. Using both national registries and a single-institution dataset, our results demonstrate that cancers with

Indexed as

NeoplasmsTumor Suppressor Protein p53Biomarkers, TumorHigh-Throughput Nucleotide SequencingHumansMutationTumor BurdenBiomarkers, TumorTP53 protein, humanTumor Suppressor Protein p53amplificationscancer genesnext-generation sequencingTP53

Identifiers

PMID36171565
PMCPMC9542347
OpenAlexW4297477283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.